Ads
related to: anaplastic thyroid cancer clinical trials
Search results
Results from the WOW.Com Content Network
The cells of anaplastic thyroid cancer are highly abnormal and usually no longer resemble the original thyroid cells and have poor differentiation. ATC is an uncommon form of thyroid cancer only accounting for 1-2% of cases, but due to its high mortality, is responsible for 20-50% of deaths from thyroid cancer. [2]
In July 2007, the pharmaceutical company OXiGENE initiated a 180-patient phase III clinical trial of fosbretabulin in combination with carboplatin for the treatment of anaplastic thyroid cancer. [3] There is currently no fully FDA approved treatment for this form of cancer.
She also has been actively involved in clinical trials focused on the development of novel therapies for the management of locally advanced and metastatic thyroid cancer; she was active in early work developing vandetanib for medullary thyroid cancer and exploring vascular disrupting agent for anaplastic thyroid cancer (Thyroid 2014).
Thyroid neoplasm is a neoplasm or tumor of the thyroid. It can be a benign tumor such as thyroid adenoma, [1] or it can be a malignant neoplasm (thyroid cancer), such as papillary, follicular, medullary or anaplastic thyroid cancer. [2] Most patients are 25 to 65 years of age when first diagnosed; women are more affected than men.
Thyroid cancer accounts for less than 1% of cancer cases and deaths in the UK. Around 2,700 people were diagnosed with thyroid cancer in the UK in 2011, and around 370 people died from the disease in 2012. [69] However, in South Korea, thyroid cancer was the 5th most prevalent cancer, which accounted for 7.7% of new cancer cases in 2020. [70]
She is elucidating the roles of thyroid hormone receptors in cancers. Cheng developed preclinical mouse models of metastatic follicular thyroid cancer and anaplastic thyroid cancer. She focuses on the elucidation of altered signaling pathways to understand the molecular genetics underlying thyroid carcinogenesis.
Crizotinib received accelerated approval in 2011 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, while cabozantinib was approved in 2012 for the treatment of medullary thyroid cancer [3] and it has also started clinical trials for the treatment of several other types of cancer.
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
Ads
related to: anaplastic thyroid cancer clinical trials